EC Number |
Activating Compound |
Reference |
---|
3.2.1.45 | (3aR,4S,5R,6R,7S,7aS)-2-(3-phenylpropylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol |
Gcase activity increase: 1.9fold and 1.4fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients |
715298 |
3.2.1.45 | (3aR,4S,5R,6R,7S,7aS)-2-(nonylimino)-octahydro-1H-benzo[d]imidazole-4,5,6,7-tetraol |
Gcase activity increase: 1.8fold and 1.4fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients |
715298 |
3.2.1.45 | (3aR,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol |
Gcase activity increase: 1.8fold and 1.4fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients |
715298 |
3.2.1.45 | (3aR,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol |
Gcase activity increase: 1.7fold and 1.3fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients |
715298 |
3.2.1.45 | (3aRS,4SR,5RS,6SR,7RS,7aRS)- 2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol |
Gcase activity increase: 1.7fold in N370S lymphoblasts from Gaucher patients |
715298 |
3.2.1.45 | (3aS,4S,5R,6S,7R,7aR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol |
Gcase activity increase: 1.4fold and 1.1fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients |
715298 |
3.2.1.45 | (3aS,4S,5R,6S,7R,7aS)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol |
Gcase activity increase: 2.1fold and 1.5fold in N370S and L44P, respectively, lymphoblasts from Gaucher patients |
715298 |
3.2.1.45 | (3aSR,4SR,5RS,6SR,7RS,7aSR)-2-(nonylimino)-octahydrobenzo[d]oxazole-4,5,6,7-tetraol |
Gcase activity increase: 1.7fold in N370S lymphoblasts from Gaucher patients |
715298 |
3.2.1.45 | (R)-4-(3-phenoxypiperidin-1-yl)-2-(pyridin-3-yl)quinazoline |
50% activation at 0.00365 mM |
751287 |
3.2.1.45 | (R)-N-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine |
50% activation at 0.00237 mM |
751287 |